Beta-Synuclein ELISA for Synaptic Degeneration Diagnosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for diagnosing synaptic degeneration in neurodegenerative diseases, such as Alzheimer's, lack a routine and efficient assay for measuring synaptic dysfunction, which is a key early indicator of disease progression and cognitive deterioration.

Innovation Solution

An ex vivo method using an enzyme-linked immunosorbent assay (ELISA) to determine beta-synuclein concentrations in cerebrospinal fluid (CSF) samples, employing capture and detection antibodies specific to beta- and alpha-synuclein, providing a sandwich ELISA assay kit for accurate diagnosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If mass spectrometric approach (MRM) is used to measure beta-synuclein in CSF, then measurement precision is improved, but productivity deteriorates due to time-consuming analysis

Engineering Contradiction:

Improvebeta-synuclein concentration measurementVSAvoiddiagnostic throughput

Core Design Contradiction:

Measurement precisionVSProductivity

Solution Approach 1:

The patent replaces the mass spectrometric measurement system with an enzyme-linked immunosorbent assay (ELISA) system. This substitution maintains the ability to measure beta-synuclein concentration with sufficient precision while dramatically improving throughput and reducing analysis time, making the diagnostic process feasible for routine clinical use.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the measurement methodology from mass spectrometry to ELISA, altering the physical and chemical parameters of the detection process. This parameter change enables parallel processing of multiple samples simultaneously, thereby improving productivity while maintaining adequate measurement precision for diagnostic purposes.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If Tau and Aβ42 markers are measured in CSF, then diagnostic accuracy for Alzheimer's disease is improved, but the ability to detect synaptic dysfunction deteriorates

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidsynaptic dysfunction information

Core Design Contradiction:

Measurement precisionVSLoss of information

Solution Approach 1:

The patent combines the measurement of traditional Alzheimer's disease markers (Tau and Aβ42) with the measurement of beta-synuclein, a synaptic marker. This merging of multiple biomarker assessments into a single diagnostic approach enables comprehensive detection of both neurodegeneration and synaptic dysfunction, preventing loss of critical diagnostic information.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent develops a universal diagnostic approach that can simultaneously assess multiple aspects of Alzheimer's disease pathology through a single ELISA-based methodology. This multi-functional diagnostic system evaluates neurodegeneration markers and synaptic dysfunction markers together, providing comprehensive diagnostic information without requiring separate specialized assays.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Loss of time

If synaptic loss is monitored early in disease progression, then early diagnosis capability is improved, but reliability of biomarker selection worsens due to lack of validated markers

Engineering Contradiction:

Improvediagnosis timingVSAvoidbiomarker validation

Core Design Contradiction:

Loss of timeVSReliability

Solution Approach 1:

The patent performs preliminary validation of beta-synuclein as a biomarker for synaptic loss in Alzheimer's disease before its routine clinical application. By establishing beta-synuclein's reliability as an early synaptic dysfunction marker through prior research and validation studies, the patent enables confident early diagnosis monitoring without compromising biomarker reliability.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively differentiates Alzheimer's disease and mild cognitive impairment from other neurodegenerative diseases, with beta-synuclein levels serving as a sensitive and specific biomarker for synaptic degeneration, enabling early diagnosis and monitoring of disease progression.

Implementation Method 1

The sandwich ELISA includes capture and detection antibodies against beta-synuclein

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

determining a concentration of beta-synuclein in the cerebrospinal fluid (CSF) by an enzyme-linked immunosorbent assay (ELISA)

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Data Source

PatentUS20230071480A1Diagnosing a Disease Associated with Synaptic Degeneration using an Elisa for Determining a Beta-Synuclein Concentration in CSF

Publication Date: 2023.03.09 OTTO MARKUS DR

AI summary

In an ex vivo method of diagnosing a disease associated with synaptic degeneration, a concentration of beta-synuclein in a cerebrospinal fluid (CSF) sample taken from a patient is determined by an enzyme-linked immunosorbent assay (ELISA).